635731-97-4 Usage
General Description
2-Bromo-4-hydroxynicotinonitrile is a chemical compound with the molecular formula C6H3BrN2O. It is identified as an intermediate used in organic synthesis. This chemical is slightly soluble in water and has a brownish appearance. As a laboratory chemical, it's used primarily in scientific research and development activities. It is important to handle and store this compound correctly, as it can cause skin and eye irritation. It should always be used in well-ventilated environments and protective equipment should be worn when handling it. As with many chemicals, the impact of 2-Bromo-4-hydroxynicotinonitrile on the environment or health is not fully known, so it's essential to treat it as potentially harmful.
Check Digit Verification of cas no
The CAS Registry Mumber 635731-97-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,3,5,7,3 and 1 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 635731-97:
(8*6)+(7*3)+(6*5)+(5*7)+(4*3)+(3*1)+(2*9)+(1*7)=174
174 % 10 = 4
So 635731-97-4 is a valid CAS Registry Number.
InChI:InChI=1/C6H3BrN2O/c7-6-4(3-8)5(10)1-2-9-6/h1-2H,(H,9,10)
635731-97-4Relevant articles and documents
ANTAGONISTS OF THE MGLU RECEPTOR AND USES THEREOF
-
Page/Page column 48, (2008/06/13)
The present invention discloses compounds of general formula (I) wherein X1-X4 and R1-R3 are as defined in the description. The present invention also discloses methods of treatment for pain, neurodegeneration and convulsive states in a host mammal in need thereof, and pharmaceutical compositions including those compounds.
SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES
-
Page 88-89, (2008/06/13)
Disclosed are compounds of formula (I), wherein R1 and R2 are defined herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.